Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts

被引:0
作者
David M. Swoboda
Rashmi Kanagal-Shamanna
Andrew M. Brunner
Thomas Cluzeau
Onyee Chan
Najla Al Ali
Guillermo Montalban-Bravo
Quinto J. Gesiotto
Alexander Gavralidis
Anthony M. Hunter
Jung-Hoon Lee
Andrew T. Kuykendall
Chetasi Talati
Kendra L. Sweet
Jeffrey E. Lancet
Eric Padron
Mohammad Hussaini
Jinming Song
Guillermo Garcia-Manero
Rami S. Komrokji
David A. Sallman
机构
[1] H. Lee Moffitt Cancer Center,Department of Malignant Hematology
[2] Tampa General Hospital Cancer Institute,Department of Hematopathology and Molecular Diagnostics
[3] The University of Texas MD Anderson Cancer Center,Massachusetts General Hospital Cancer Center
[4] Harvard Medical School,Department of Hematology
[5] CHU of Nice,Department of Leukemia
[6] The University of Texas MD Anderson Cancer Center,Department of Medicine
[7] University of South Florida,Department of Internal Medicine
[8] Mass General Brigham Salem Hospital,Department of Hematology and Medical Oncology
[9] Emory University School of Medicine,Department of Hematology and Medical Oncology
[10] Weill Cornell Medical College,Department of Pathology
[11] H. Lee Moffitt Cancer Center,undefined
来源
Leukemia | 2022年 / 36卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1189 / 1192
页数:3
相关论文
共 57 条
[1]  
Arber DA(2016)The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia Blood 127 2391-405
[2]  
Orazi A(2015)SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts Blood 126 233-41
[3]  
Hasserjian R(2011)Frequent pathway mutations of splicing machinery in myelodysplasia Nature 478 64-9
[4]  
Thiele J(2011)Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts N. Engl J Med 365 1384-95
[5]  
Borowitz MJ(2020)SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS Blood 136 157-70
[6]  
Le Beau MM(2011)Clinical effect of point mutations in myelodysplastic syndromes N. Engl J Med 364 2496-506
[7]  
Malcovati L(2014)Landscape of genetic lesions in 944 patients with myelodysplastic syndromes Leukemia 28 241-7
[8]  
Karimi M(2019)TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups Leukemia 33 1747-58
[9]  
Papaemmanuil E(2020)The Problem of TP53-Mutant MDS/AML Clin Lymphoma Myeloma Leuk 20 S65-S6
[10]  
Ambaglio I(2008)Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts Haematologica 93 1712-7